In	B:C1515655
Vivo	I:C1515655
Expansion	O
of	O
Melanoma	O
-	O
Specific	O
T	O
Cells	I:C0039194
Using	O
Microneedle	O
Arrays	O
Coated	O
with	O
Immune	O
-	I:C0005479
Polyelectrolyte	I:C0005479
Multilayers	I:C0005479
.	O

In	O
Vivo	I:C1515655
Expansion	B:C0007595
of	O
Melanoma	O
-	O
Specific	O
T	O
Cells	I:C0039194
Using	O
Microneedle	O
Arrays	O
Coated	O
with	O
Immune	O
-	I:C0005479
Polyelectrolyte	I:C0005479
Multilayers	I:C0005479
.	O

In	O
Vivo	I:C1515655
Expansion	O
of	O
Melanoma	B:C0025202
-	O
Specific	O
T	O
Cells	I:C0039194
Using	O
Microneedle	O
Arrays	O
Coated	O
with	O
Immune	O
-	I:C0005479
Polyelectrolyte	I:C0005479
Multilayers	I:C0005479
.	O

In	O
Vivo	I:C1515655
Expansion	O
of	O
Melanoma	O
-	O
Specific	O
T	B:C0039194
Cells	I:C0039194
Using	O
Microneedle	O
Arrays	O
Coated	O
with	O
Immune	O
-	I:C0005479
Polyelectrolyte	I:C0005479
Multilayers	I:C0005479
.	O

In	O
Vivo	I:C1515655
Expansion	O
of	O
Melanoma	O
-	O
Specific	O
T	O
Cells	I:C0039194
Using	O
Microneedle	B:C0027551
Arrays	O
Coated	O
with	O
Immune	O
-	I:C0005479
Polyelectrolyte	I:C0005479
Multilayers	I:C0005479
.	O

In	O
Vivo	I:C1515655
Expansion	O
of	O
Melanoma	O
-	O
Specific	O
T	O
Cells	I:C0039194
Using	O
Microneedle	O
Arrays	O
Coated	O
with	O
Immune	B:C0005479
-	I:C0005479
Polyelectrolyte	I:C0005479
Multilayers	I:C0005479
.	O

Microneedles	B:C0027551
(	O
Microneedles	O
)	O
are	O
micron	O
-	O
scale	O
polymeric	O
or	O
metallic	O
structures	O
that	O
offer	O
distinct	O
advantages	O
for	O
vaccines	O
by	O
efficiently	O
targeting	O
skin	O
-	O
resident	O
immune	O
cells	I:C0312740
,	O
eliminating	O
injection	O
-	I:C1096717
associated	I:C1096717
pain	I:C1096717
,	O
and	O
improving	O
patient	O
compliance	O
.	O

Microneedles	O
(	O
Microneedles	B:C0027551
)	O
are	O
micron	O
-	O
scale	O
polymeric	O
or	O
metallic	O
structures	O
that	O
offer	O
distinct	O
advantages	O
for	O
vaccines	O
by	O
efficiently	O
targeting	O
skin	O
-	O
resident	O
immune	O
cells	I:C0312740
,	O
eliminating	O
injection	O
-	I:C1096717
associated	I:C1096717
pain	I:C1096717
,	O
and	O
improving	O
patient	O
compliance	O
.	O

Microneedles	O
(	O
Microneedles	O
)	O
are	O
micron	O
-	O
scale	O
polymeric	B:C0032521
or	O
metallic	O
structures	O
that	O
offer	O
distinct	O
advantages	O
for	O
vaccines	O
by	O
efficiently	O
targeting	O
skin	O
-	O
resident	O
immune	O
cells	I:C0312740
,	O
eliminating	O
injection	O
-	I:C1096717
associated	I:C1096717
pain	I:C1096717
,	O
and	O
improving	O
patient	O
compliance	O
.	O

Microneedles	O
(	O
Microneedles	O
)	O
are	O
micron	O
-	O
scale	O
polymeric	O
or	O
metallic	O
structures	O
that	O
offer	O
distinct	O
advantages	O
for	O
vaccines	B:C0042210
by	O
efficiently	O
targeting	O
skin	O
-	O
resident	O
immune	O
cells	I:C0312740
,	O
eliminating	O
injection	O
-	I:C1096717
associated	I:C1096717
pain	I:C1096717
,	O
and	O
improving	O
patient	O
compliance	O
.	O

Microneedles	O
(	O
Microneedles	O
)	O
are	O
micron	O
-	O
scale	O
polymeric	O
or	O
metallic	O
structures	O
that	O
offer	O
distinct	O
advantages	O
for	O
vaccines	O
by	O
efficiently	O
targeting	O
skin	B:C1123023
-	O
resident	O
immune	O
cells	I:C0312740
,	O
eliminating	O
injection	O
-	I:C1096717
associated	I:C1096717
pain	I:C1096717
,	O
and	O
improving	O
patient	O
compliance	O
.	O

Microneedles	O
(	O
Microneedles	O
)	O
are	O
micron	O
-	O
scale	O
polymeric	O
or	O
metallic	O
structures	O
that	O
offer	O
distinct	O
advantages	O
for	O
vaccines	O
by	O
efficiently	O
targeting	O
skin	O
-	O
resident	O
immune	B:C0312740
cells	I:C0312740
,	O
eliminating	O
injection	O
-	I:C1096717
associated	I:C1096717
pain	I:C1096717
,	O
and	O
improving	O
patient	O
compliance	O
.	O

Microneedles	O
(	O
Microneedles	O
)	O
are	O
micron	O
-	O
scale	O
polymeric	O
or	O
metallic	O
structures	O
that	O
offer	O
distinct	O
advantages	O
for	O
vaccines	O
by	O
efficiently	O
targeting	O
skin	O
-	O
resident	O
immune	O
cells	I:C0312740
,	O
eliminating	O
injection	B:C1096717
-	I:C1096717
associated	I:C1096717
pain	I:C1096717
,	O
and	O
improving	O
patient	O
compliance	O
.	O

These	O
advantages	O
,	O
along	O
with	O
recent	O
studies	B:C2603343
showing	O
therapeutic	O
benefits	O
achieved	O
using	O
traditional	O
intradermal	O
injections	I:C0021489
in	O
human	O
cancer	O
patients	O
,	O
suggest	O
MN	O
delivery	O
might	O
enhance	O
cancer	O
vaccines	I:C0376659
and	O
immunotherapies	O
.	O

These	O
advantages	O
,	O
along	O
with	O
recent	O
studies	O
showing	O
therapeutic	O
benefits	O
achieved	O
using	O
traditional	O
intradermal	B:C0021489
injections	I:C0021489
in	O
human	O
cancer	O
patients	O
,	O
suggest	O
MN	O
delivery	O
might	O
enhance	O
cancer	O
vaccines	I:C0376659
and	O
immunotherapies	O
.	O

These	O
advantages	O
,	O
along	O
with	O
recent	O
studies	O
showing	O
therapeutic	O
benefits	O
achieved	O
using	O
traditional	O
intradermal	O
injections	I:C0021489
in	O
human	B:C0086418
cancer	O
patients	O
,	O
suggest	O
MN	O
delivery	O
might	O
enhance	O
cancer	O
vaccines	I:C0376659
and	O
immunotherapies	O
.	O

These	O
advantages	O
,	O
along	O
with	O
recent	O
studies	O
showing	O
therapeutic	O
benefits	O
achieved	O
using	O
traditional	O
intradermal	O
injections	I:C0021489
in	O
human	O
cancer	O
patients	O
,	O
suggest	O
MN	B:C0027551
delivery	O
might	O
enhance	O
cancer	O
vaccines	I:C0376659
and	O
immunotherapies	O
.	O

These	O
advantages	O
,	O
along	O
with	O
recent	O
studies	O
showing	O
therapeutic	O
benefits	O
achieved	O
using	O
traditional	O
intradermal	O
injections	I:C0021489
in	O
human	O
cancer	O
patients	O
,	O
suggest	O
MN	O
delivery	O
might	O
enhance	O
cancer	B:C0376659
vaccines	I:C0376659
and	O
immunotherapies	O
.	O

These	O
advantages	O
,	O
along	O
with	O
recent	O
studies	O
showing	O
therapeutic	O
benefits	O
achieved	O
using	O
traditional	O
intradermal	O
injections	I:C0021489
in	O
human	O
cancer	O
patients	O
,	O
suggest	O
MN	O
delivery	O
might	O
enhance	O
cancer	O
vaccines	I:C0376659
and	O
immunotherapies	B:C0021083
.	O

We	O
recently	O
developed	O
a	O
new	O
class	O
of	O
polyelectrolyte	B:C0005479
multilayers	I:C0005479
based	O
on	O
the	O
self	O
-	O
assembly	O
of	O
model	O
peptide	O
antigens	I:C0003320
and	O
molecular	O
toll	I:C0243192
-	I:C0243192
like	I:C0243192
receptor	I:C0243192
agonists	I:C0243192
(	O
toll	O
-	I:C0243192
like	I:C0243192
receptor	I:C0243192
agonists	I:C0243192
)	O
into	O
ultrathin	O
,	O
conformal	O
coatings	O
.	O

We	O
recently	O
developed	O
a	O
new	O
class	O
of	O
polyelectrolyte	O
multilayers	I:C0005479
based	O
on	O
the	O
self	O
-	O
assembly	O
of	O
model	O
peptide	B:C0003320
antigens	I:C0003320
and	O
molecular	O
toll	I:C0243192
-	I:C0243192
like	I:C0243192
receptor	I:C0243192
agonists	I:C0243192
(	O
toll	O
-	I:C0243192
like	I:C0243192
receptor	I:C0243192
agonists	I:C0243192
)	O
into	O
ultrathin	O
,	O
conformal	O
coatings	O
.	O

We	O
recently	O
developed	O
a	O
new	O
class	O
of	O
polyelectrolyte	O
multilayers	I:C0005479
based	O
on	O
the	O
self	O
-	O
assembly	O
of	O
model	O
peptide	O
antigens	I:C0003320
and	O
molecular	B:C0243192
toll	I:C0243192
-	I:C0243192
like	I:C0243192
receptor	I:C0243192
agonists	I:C0243192
(	O
toll	O
-	I:C0243192
like	I:C0243192
receptor	I:C0243192
agonists	I:C0243192
)	O
into	O
ultrathin	O
,	O
conformal	O
coatings	O
.	O

We	O
recently	O
developed	O
a	O
new	O
class	O
of	O
polyelectrolyte	O
multilayers	I:C0005479
based	O
on	O
the	O
self	O
-	O
assembly	O
of	O
model	O
peptide	O
antigens	I:C0003320
and	O
molecular	O
toll	I:C0243192
-	I:C0243192
like	I:C0243192
receptor	I:C0243192
agonists	I:C0243192
(	O
toll	B:C0243192
-	I:C0243192
like	I:C0243192
receptor	I:C0243192
agonists	I:C0243192
)	O
into	O
ultrathin	O
,	O
conformal	O
coatings	O
.	O

Here	O
,	O
we	O
reasoned	O
that	O
these	O
immune	B:C0005479
polyelectrolyte	I:C0005479
multilayers	I:C0005479
(	O
immune	O
polyelectrolyte	I:C0005479
multilayers	I:C0005479
)	O
might	O
be	O
a	O
useful	O
platform	O
for	O
assembling	O
cancer	O
vaccine	I:C0376659
components	O
on	O
MN	O
arrays	O
for	O
intradermal	O
delivery	I:C0021489
from	O
these	O
substrates	O
.	O

Here	O
,	O
we	O
reasoned	O
that	O
these	O
immune	O
polyelectrolyte	I:C0005479
multilayers	I:C0005479
(	O
immune	B:C0005479
polyelectrolyte	I:C0005479
multilayers	I:C0005479
)	O
might	O
be	O
a	O
useful	O
platform	O
for	O
assembling	O
cancer	O
vaccine	I:C0376659
components	O
on	O
MN	O
arrays	O
for	O
intradermal	O
delivery	I:C0021489
from	O
these	O
substrates	O
.	O

Here	O
,	O
we	O
reasoned	O
that	O
these	O
immune	O
polyelectrolyte	I:C0005479
multilayers	I:C0005479
(	O
immune	O
polyelectrolyte	I:C0005479
multilayers	I:C0005479
)	O
might	O
be	O
a	O
useful	O
platform	O
for	O
assembling	O
cancer	B:C0376659
vaccine	I:C0376659
components	O
on	O
MN	O
arrays	O
for	O
intradermal	O
delivery	I:C0021489
from	O
these	O
substrates	O
.	O

Here	O
,	O
we	O
reasoned	O
that	O
these	O
immune	O
polyelectrolyte	I:C0005479
multilayers	I:C0005479
(	O
immune	O
polyelectrolyte	I:C0005479
multilayers	I:C0005479
)	O
might	O
be	O
a	O
useful	O
platform	O
for	O
assembling	O
cancer	O
vaccine	I:C0376659
components	O
on	O
MN	B:C0027551
arrays	O
for	O
intradermal	O
delivery	I:C0021489
from	O
these	O
substrates	O
.	O

Here	O
,	O
we	O
reasoned	O
that	O
these	O
immune	O
polyelectrolyte	I:C0005479
multilayers	I:C0005479
(	O
immune	O
polyelectrolyte	I:C0005479
multilayers	I:C0005479
)	O
might	O
be	O
a	O
useful	O
platform	O
for	O
assembling	O
cancer	O
vaccine	I:C0376659
components	O
on	O
MN	O
arrays	O
for	O
intradermal	B:C0021489
delivery	I:C0021489
from	O
these	O
substrates	O
.	O

Using	O
conserved	O
human	B:C0086418
melanoma	O
antigens	I:C2936596
and	O
a	O
potent	O
TLRa	O
vaccine	I:C0243192
adjuvant	O
,	O
CpG	O
,	O
we	O
show	O
that	O
immune	O
polyelectrolyte	I:C0005479
multilayers	I:C0005479
can	O
be	O
assembled	O
on	O
Microneedles	O
in	O
an	O
automated	O
fashion	O
.	O

Using	O
conserved	O
human	O
melanoma	B:C2936596
antigens	I:C2936596
and	O
a	O
potent	O
TLRa	O
vaccine	I:C0243192
adjuvant	O
,	O
CpG	O
,	O
we	O
show	O
that	O
immune	O
polyelectrolyte	I:C0005479
multilayers	I:C0005479
can	O
be	O
assembled	O
on	O
Microneedles	O
in	O
an	O
automated	O
fashion	O
.	O

Using	O
conserved	O
human	O
melanoma	O
antigens	I:C2936596
and	O
a	O
potent	O
TLRa	B:C0243192
vaccine	I:C0243192
adjuvant	O
,	O
CpG	O
,	O
we	O
show	O
that	O
immune	O
polyelectrolyte	I:C0005479
multilayers	I:C0005479
can	O
be	O
assembled	O
on	O
Microneedles	O
in	O
an	O
automated	O
fashion	O
.	O

Using	O
conserved	O
human	O
melanoma	O
antigens	I:C2936596
and	O
a	O
potent	O
TLRa	O
vaccine	I:C0243192
adjuvant	O
,	O
CpG	B:C0042210
,	O
we	O
show	O
that	O
immune	O
polyelectrolyte	I:C0005479
multilayers	I:C0005479
can	O
be	O
assembled	O
on	O
Microneedles	O
in	O
an	O
automated	O
fashion	O
.	O

Using	O
conserved	O
human	O
melanoma	O
antigens	I:C2936596
and	O
a	O
potent	O
TLRa	O
vaccine	I:C0243192
adjuvant	O
,	O
CpG	O
,	O
we	O
show	O
that	O
immune	B:C0005479
polyelectrolyte	I:C0005479
multilayers	I:C0005479
can	O
be	O
assembled	O
on	O
Microneedles	O
in	O
an	O
automated	O
fashion	O
.	O

Using	O
conserved	O
human	O
melanoma	O
antigens	I:C2936596
and	O
a	O
potent	O
TLRa	O
vaccine	I:C0243192
adjuvant	O
,	O
CpG	O
,	O
we	O
show	O
that	O
immune	O
polyelectrolyte	I:C0005479
multilayers	I:C0005479
can	O
be	O
assembled	O
on	O
Microneedles	B:C0027551
in	O
an	O
automated	O
fashion	O
.	O

These	O
films	O
,	O
prepared	O
with	O
up	O
to	O
128	O
layers	O
,	O
are	O
approximately	O
200	O
nm	O
thick	O
but	O
provide	O
cancer	B:C0376659
vaccine	I:C0376659
cargo	O
loading	O
>225	O
μg/	O
cm	O
(	O
2	O
)	O
.	O

In	O
cell	B:C0007585
culture	I:C0007585
,	O
iPEM	O
cargo	O
released	O
from	O
Microneedles	O
is	O
internalized	O
by	O
primary	O
dendritic	O
cells	I:C0011306
,	O
promotes	O
activation	O
of	O
these	O
cells	O
,	O
and	O
expands	O
T	O
cells	I:C0039194
during	O
coculture	O
.	O

In	O
cell	O
culture	I:C0007585
,	O
iPEM	B:C0005479
cargo	O
released	O
from	O
Microneedles	O
is	O
internalized	O
by	O
primary	O
dendritic	O
cells	I:C0011306
,	O
promotes	O
activation	O
of	O
these	O
cells	O
,	O
and	O
expands	O
T	O
cells	I:C0039194
during	O
coculture	O
.	O

In	O
cell	O
culture	I:C0007585
,	O
iPEM	O
cargo	O
released	O
from	O
Microneedles	B:C0027551
is	O
internalized	O
by	O
primary	O
dendritic	O
cells	I:C0011306
,	O
promotes	O
activation	O
of	O
these	O
cells	O
,	O
and	O
expands	O
T	O
cells	I:C0039194
during	O
coculture	O
.	O

In	O
cell	O
culture	I:C0007585
,	O
iPEM	O
cargo	O
released	O
from	O
Microneedles	O
is	O
internalized	O
by	O
primary	O
dendritic	B:C0011306
cells	I:C0011306
,	O
promotes	O
activation	O
of	O
these	O
cells	O
,	O
and	O
expands	O
T	O
cells	I:C0039194
during	O
coculture	O
.	O

In	O
cell	O
culture	I:C0007585
,	O
iPEM	O
cargo	O
released	O
from	O
Microneedles	O
is	O
internalized	O
by	O
primary	O
dendritic	O
cells	I:C0011306
,	O
promotes	O
activation	O
of	O
these	O
cells	B:C0007634
,	O
and	O
expands	O
T	O
cells	I:C0039194
during	O
coculture	O
.	O

In	O
cell	O
culture	I:C0007585
,	O
iPEM	O
cargo	O
released	O
from	O
Microneedles	O
is	O
internalized	O
by	O
primary	O
dendritic	O
cells	I:C0011306
,	O
promotes	O
activation	O
of	O
these	O
cells	O
,	O
and	O
expands	O
T	B:C0039194
cells	I:C0039194
during	O
coculture	O
.	O

In	O
cell	O
culture	I:C0007585
,	O
iPEM	O
cargo	O
released	O
from	O
Microneedles	O
is	O
internalized	O
by	O
primary	O
dendritic	O
cells	I:C0011306
,	O
promotes	O
activation	O
of	O
these	O
cells	O
,	O
and	O
expands	O
T	O
cells	I:C0039194
during	O
coculture	B:C0282547
.	O

In	O
mice	B:C0025929
,	O
application	O
of	O
iPEM	O
-	O
coated	O
Microneedles	O
results	O
in	O
the	O
codelivery	O
of	O
tumor	O
antigen	O
and	O
CpG	O
through	O
the	O
skin	O
,	O
expanding	O
tumor	O
-	O
specific	O
T	O
cells	I:C0039194
during	O
initial	O
MN	O
applications	O
and	O
resulting	O
in	O
larger	O
memory	O
recall	I:C0679063
responses	I:C0679063
during	O
a	O
subsequent	O
booster	O
MN	O
application	O
.	O

In	O
mice	O
,	O
application	B:C0185125
of	O
iPEM	O
-	O
coated	O
Microneedles	O
results	O
in	O
the	O
codelivery	O
of	O
tumor	O
antigen	O
and	O
CpG	O
through	O
the	O
skin	O
,	O
expanding	O
tumor	O
-	O
specific	O
T	O
cells	I:C0039194
during	O
initial	O
MN	O
applications	O
and	O
resulting	O
in	O
larger	O
memory	O
recall	I:C0679063
responses	I:C0679063
during	O
a	O
subsequent	O
booster	O
MN	O
application	O
.	O

In	O
mice	O
,	O
application	O
of	O
iPEM	B:C0005479
-	O
coated	O
Microneedles	O
results	O
in	O
the	O
codelivery	O
of	O
tumor	O
antigen	O
and	O
CpG	O
through	O
the	O
skin	O
,	O
expanding	O
tumor	O
-	O
specific	O
T	O
cells	I:C0039194
during	O
initial	O
MN	O
applications	O
and	O
resulting	O
in	O
larger	O
memory	O
recall	I:C0679063
responses	I:C0679063
during	O
a	O
subsequent	O
booster	O
MN	O
application	O
.	O

In	O
mice	O
,	O
application	O
of	O
iPEM	O
-	O
coated	O
Microneedles	B:C0027551
results	O
in	O
the	O
codelivery	O
of	O
tumor	O
antigen	O
and	O
CpG	O
through	O
the	O
skin	O
,	O
expanding	O
tumor	O
-	O
specific	O
T	O
cells	I:C0039194
during	O
initial	O
MN	O
applications	O
and	O
resulting	O
in	O
larger	O
memory	O
recall	I:C0679063
responses	I:C0679063
during	O
a	O
subsequent	O
booster	O
MN	O
application	O
.	O

In	O
mice	O
,	O
application	O
of	O
iPEM	O
-	O
coated	O
Microneedles	O
results	O
in	O
the	O
codelivery	O
of	O
tumor	B:C0027651
antigen	O
and	O
CpG	O
through	O
the	O
skin	O
,	O
expanding	O
tumor	O
-	O
specific	O
T	O
cells	I:C0039194
during	O
initial	O
MN	O
applications	O
and	O
resulting	O
in	O
larger	O
memory	O
recall	I:C0679063
responses	I:C0679063
during	O
a	O
subsequent	O
booster	O
MN	O
application	O
.	O

In	O
mice	O
,	O
application	O
of	O
iPEM	O
-	O
coated	O
Microneedles	O
results	O
in	O
the	O
codelivery	O
of	O
tumor	O
antigen	B:C0003320
and	O
CpG	O
through	O
the	O
skin	O
,	O
expanding	O
tumor	O
-	O
specific	O
T	O
cells	I:C0039194
during	O
initial	O
MN	O
applications	O
and	O
resulting	O
in	O
larger	O
memory	O
recall	I:C0679063
responses	I:C0679063
during	O
a	O
subsequent	O
booster	O
MN	O
application	O
.	O

In	O
mice	O
,	O
application	O
of	O
iPEM	O
-	O
coated	O
Microneedles	O
results	O
in	O
the	O
codelivery	O
of	O
tumor	O
antigen	O
and	O
CpG	B:C0042210
through	O
the	O
skin	O
,	O
expanding	O
tumor	O
-	O
specific	O
T	O
cells	I:C0039194
during	O
initial	O
MN	O
applications	O
and	O
resulting	O
in	O
larger	O
memory	O
recall	I:C0679063
responses	I:C0679063
during	O
a	O
subsequent	O
booster	O
MN	O
application	O
.	O

In	O
mice	O
,	O
application	O
of	O
iPEM	O
-	O
coated	O
Microneedles	O
results	O
in	O
the	O
codelivery	O
of	O
tumor	O
antigen	O
and	O
CpG	O
through	O
the	O
skin	B:C1123023
,	O
expanding	O
tumor	O
-	O
specific	O
T	O
cells	I:C0039194
during	O
initial	O
MN	O
applications	O
and	O
resulting	O
in	O
larger	O
memory	O
recall	I:C0679063
responses	I:C0679063
during	O
a	O
subsequent	O
booster	O
MN	O
application	O
.	O

In	O
mice	O
,	O
application	O
of	O
iPEM	O
-	O
coated	O
Microneedles	O
results	O
in	O
the	O
codelivery	O
of	O
tumor	O
antigen	O
and	O
CpG	O
through	O
the	O
skin	O
,	O
expanding	O
tumor	B:C0027651
-	O
specific	O
T	O
cells	I:C0039194
during	O
initial	O
MN	O
applications	O
and	O
resulting	O
in	O
larger	O
memory	O
recall	I:C0679063
responses	I:C0679063
during	O
a	O
subsequent	O
booster	O
MN	O
application	O
.	O

In	O
mice	O
,	O
application	O
of	O
iPEM	O
-	O
coated	O
Microneedles	O
results	O
in	O
the	O
codelivery	O
of	O
tumor	O
antigen	O
and	O
CpG	O
through	O
the	O
skin	O
,	O
expanding	O
tumor	O
-	O
specific	O
T	B:C0039194
cells	I:C0039194
during	O
initial	O
MN	O
applications	O
and	O
resulting	O
in	O
larger	O
memory	O
recall	I:C0679063
responses	I:C0679063
during	O
a	O
subsequent	O
booster	O
MN	O
application	O
.	O

In	O
mice	O
,	O
application	O
of	O
iPEM	O
-	O
coated	O
Microneedles	O
results	O
in	O
the	O
codelivery	O
of	O
tumor	O
antigen	O
and	O
CpG	O
through	O
the	O
skin	O
,	O
expanding	O
tumor	O
-	O
specific	O
T	O
cells	I:C0039194
during	O
initial	O
MN	B:C0027551
applications	O
and	O
resulting	O
in	O
larger	O
memory	O
recall	I:C0679063
responses	I:C0679063
during	O
a	O
subsequent	O
booster	O
MN	O
application	O
.	O

In	O
mice	O
,	O
application	O
of	O
iPEM	O
-	O
coated	O
Microneedles	O
results	O
in	O
the	O
codelivery	O
of	O
tumor	O
antigen	O
and	O
CpG	O
through	O
the	O
skin	O
,	O
expanding	O
tumor	O
-	O
specific	O
T	O
cells	I:C0039194
during	O
initial	O
MN	O
applications	B:C0185125
and	O
resulting	O
in	O
larger	O
memory	O
recall	I:C0679063
responses	I:C0679063
during	O
a	O
subsequent	O
booster	O
MN	O
application	O
.	O

In	O
mice	O
,	O
application	O
of	O
iPEM	O
-	O
coated	O
Microneedles	O
results	O
in	O
the	O
codelivery	O
of	O
tumor	O
antigen	O
and	O
CpG	O
through	O
the	O
skin	O
,	O
expanding	O
tumor	O
-	O
specific	O
T	O
cells	I:C0039194
during	O
initial	O
MN	O
applications	O
and	O
resulting	O
in	O
larger	O
memory	B:C0679063
recall	I:C0679063
responses	I:C0679063
during	O
a	O
subsequent	O
booster	O
MN	O
application	O
.	O

In	O
mice	O
,	O
application	O
of	O
iPEM	O
-	O
coated	O
Microneedles	O
results	O
in	O
the	O
codelivery	O
of	O
tumor	O
antigen	O
and	O
CpG	O
through	O
the	O
skin	O
,	O
expanding	O
tumor	O
-	O
specific	O
T	O
cells	I:C0039194
during	O
initial	O
MN	O
applications	O
and	O
resulting	O
in	O
larger	O
memory	O
recall	I:C0679063
responses	I:C0679063
during	O
a	O
subsequent	O
booster	O
MN	B:C0027551
application	O
.	O

In	O
mice	O
,	O
application	O
of	O
iPEM	O
-	O
coated	O
Microneedles	O
results	O
in	O
the	O
codelivery	O
of	O
tumor	O
antigen	O
and	O
CpG	O
through	O
the	O
skin	O
,	O
expanding	O
tumor	O
-	O
specific	O
T	O
cells	I:C0039194
during	O
initial	O
MN	O
applications	O
and	O
resulting	O
in	O
larger	O
memory	O
recall	I:C0679063
responses	I:C0679063
during	O
a	O
subsequent	O
booster	O
MN	O
application	B:C0185125
.	O

This	O
study	B:C2603343
support	O
Microneedles	O
coated	O
with	O
PEMs	O
built	O
from	O
tumor	O
vaccine	O
components	O
as	O
a	O
well	O
-	O
defined	O
,	O
modular	O
system	O
for	O
generating	O
tumor	O
-	O
specific	O
immune	O
responses	I:C0301872
,	O
enabling	O
new	O
approaches	O
that	O
can	O
be	O
explored	O
in	O
combination	O
with	O
checkpoint	O
blockade	O
or	O
other	O
combination	O
cancer	O
therapies	I:C0920425
.	O

This	O
study	O
support	O
Microneedles	B:C0027551
coated	O
with	O
PEMs	O
built	O
from	O
tumor	O
vaccine	O
components	O
as	O
a	O
well	O
-	O
defined	O
,	O
modular	O
system	O
for	O
generating	O
tumor	O
-	O
specific	O
immune	O
responses	I:C0301872
,	O
enabling	O
new	O
approaches	O
that	O
can	O
be	O
explored	O
in	O
combination	O
with	O
checkpoint	O
blockade	O
or	O
other	O
combination	O
cancer	O
therapies	I:C0920425
.	O

This	O
study	O
support	O
Microneedles	O
coated	O
with	O
PEMs	B:C0005479
built	O
from	O
tumor	O
vaccine	O
components	O
as	O
a	O
well	O
-	O
defined	O
,	O
modular	O
system	O
for	O
generating	O
tumor	O
-	O
specific	O
immune	O
responses	I:C0301872
,	O
enabling	O
new	O
approaches	O
that	O
can	O
be	O
explored	O
in	O
combination	O
with	O
checkpoint	O
blockade	O
or	O
other	O
combination	O
cancer	O
therapies	I:C0920425
.	O

This	O
study	O
support	O
Microneedles	O
coated	O
with	O
PEMs	O
built	O
from	O
tumor	B:C0027651
vaccine	O
components	O
as	O
a	O
well	O
-	O
defined	O
,	O
modular	O
system	O
for	O
generating	O
tumor	O
-	O
specific	O
immune	O
responses	I:C0301872
,	O
enabling	O
new	O
approaches	O
that	O
can	O
be	O
explored	O
in	O
combination	O
with	O
checkpoint	O
blockade	O
or	O
other	O
combination	O
cancer	O
therapies	I:C0920425
.	O

This	O
study	O
support	O
Microneedles	O
coated	O
with	O
PEMs	O
built	O
from	O
tumor	O
vaccine	B:C0042210
components	O
as	O
a	O
well	O
-	O
defined	O
,	O
modular	O
system	O
for	O
generating	O
tumor	O
-	O
specific	O
immune	O
responses	I:C0301872
,	O
enabling	O
new	O
approaches	O
that	O
can	O
be	O
explored	O
in	O
combination	O
with	O
checkpoint	O
blockade	O
or	O
other	O
combination	O
cancer	O
therapies	I:C0920425
.	O

This	O
study	O
support	O
Microneedles	O
coated	O
with	O
PEMs	O
built	O
from	O
tumor	O
vaccine	O
components	O
as	O
a	O
well	O
-	O
defined	O
,	O
modular	O
system	O
for	O
generating	O
tumor	B:C0027651
-	O
specific	O
immune	O
responses	I:C0301872
,	O
enabling	O
new	O
approaches	O
that	O
can	O
be	O
explored	O
in	O
combination	O
with	O
checkpoint	O
blockade	O
or	O
other	O
combination	O
cancer	O
therapies	I:C0920425
.	O

This	O
study	O
support	O
Microneedles	O
coated	O
with	O
PEMs	O
built	O
from	O
tumor	O
vaccine	O
components	O
as	O
a	O
well	O
-	O
defined	O
,	O
modular	O
system	O
for	O
generating	O
tumor	O
-	O
specific	O
immune	B:C0301872
responses	I:C0301872
,	O
enabling	O
new	O
approaches	O
that	O
can	O
be	O
explored	O
in	O
combination	O
with	O
checkpoint	O
blockade	O
or	O
other	O
combination	O
cancer	O
therapies	I:C0920425
.	O

This	O
study	O
support	O
Microneedles	O
coated	O
with	O
PEMs	O
built	O
from	O
tumor	O
vaccine	O
components	O
as	O
a	O
well	O
-	O
defined	O
,	O
modular	O
system	O
for	O
generating	O
tumor	O
-	O
specific	O
immune	O
responses	I:C0301872
,	O
enabling	O
new	O
approaches	O
that	O
can	O
be	O
explored	O
in	O
combination	O
with	O
checkpoint	O
blockade	O
or	O
other	O
combination	O
cancer	B:C0920425
therapies	I:C0920425
.	O

